New research suggests that people who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt conventional lifestyle plans.
Published data in a prominent medical journal demonstrates that while obese individuals often shed substantial amounts of their total mass while using the jabs, the weight comes back at an average rate of nearly a kilo each month once they quit.
"Individuals buying such drugs need to be cognizant of the potential of fast weight regain when the treatment concludes," warns expert Dr. Susan Jebb.
Such speed of regain means a reversion to pre-treatment weight within about 18 months.
Analyzing Treatments
The analysis, which looked at dozens of studies involving thousands of patients, compared the results of GLP-1 agonists with older methods.
Researchers emphasize that people who shed pounds through dieting usually experience a slower weight regain—around 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Experts suggest the way of the drugs is key to understanding the amplified regain.
These medications copy a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of GLP-1 levels several times higher than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication means appetite is unsuppressed, making binge eating far more likely."
A Lifelong Disease?
Medical guidelines advise the jabs for people with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians say that, due to the significant potential of relapse, the therapy might need to be long-term.
This perspective is echoed by drug manufacturers, who note that the results "highlight the persistent nature of obesity," akin to managing conditions like diabetes.
Patient Experiences
Individuals who have come off the jabs report a sudden resurgence of hunger.
"I experienced something flipping and you become extremely hungry," recalled a patient.
This difficulty is exacerbated if individuals have not developed lasting lifestyle or habit modifications during therapy.
Widespread Use
Figures suggest that millions of adults in the UK have tried these injections in the last 12 months, with demand being substantial.
- Adoption is higher among females compared to men.
- The middle-aged age group shows the greatest usage rates.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, researchers caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent solution and maintained weight loss hinges on ongoing behavioural management.
